Coronary Adventitial Inflammation as a Trigger of Vascular Remodeling

Abstract

Coronary adventitial inflammation has emerged as a critical factor in the pathogenesis of vascular remodeling, challenging the traditional intima-centric paradigm of atherosclerosis and coronary artery disease. Recent evidence underscores the significance of the adventitia, not merely as a passive structural layer, but as an active participant in vascular injury response, immune modulation, and disease progression. This review synthesizes contemporary research on the mechanisms by which adventitial inflammation triggers and sustains vascular remodeling, elaborates on epidemiology, risk factors, clinical manifestations, diagnostic modalities, therapeutic strategies, and recent advances. Practical implications for clinicians are discussed, integrating guideline-based recommendations to optimize patient outcomes.

Introduction

Vascular remodeling, a hallmark of coronary artery disease (CAD), is a dynamic process involving structural and functional changes in the vessel wall. Traditionally, attention has focused on the intimal and medial layers, emphasizing the roles of endothelial dysfunction, lipid deposition, and smooth muscle cell proliferation. However, emerging data highlight the adventitia as a key orchestrator of vascular remodeling, particularly through inflammation-mediated pathways. Adventitial inflammation influences the progression, stability, and clinical consequences of atherosclerotic lesions, making its understanding vital for clinicians managing coronary pathology.

Epidemiology / Disease Burden

CAD remains the leading cause of morbidity and mortality worldwide, accounting for an estimated 17.9 million deaths annually. While traditional risk factors such as hypertension, dyslipidemia, diabetes, and smoking are well established, the contribution of vascular inflammation, specifically within the adventitia, is increasingly recognized. Studies utilizing advanced imaging and histopathological analysis have detected adventitial inflammation in both early and advanced coronary lesions, correlating with adverse cardiovascular events and poorer long-term outcomes.

Pathophysiology

The coronary adventitia comprises connective tissue, vasa vasorum, fibroblasts, nerve fibers, and resident immune cells. In response to vascular injury or atherogenic stimuli, the adventitia undergoes inflammatory activation. This is characterized by recruitment and activation of macrophages, T-cells, dendritic cells, and mast cells, producing pro-inflammatory cytokines (e.g., IL-1β, TNF-α, IFN-γ), growth factors, and matrix metalloproteinases. These mediators promote neoangiogenesis via the vasa vasorum, facilitate immune cell trafficking, and perpetuate a cycle of local inflammation. Signals from the adventitia can traverse the medial layer, influencing smooth muscle cell phenotype, promoting migration and proliferation, and contributing to extracellular matrix remodeling. This bidirectional communication between adventitia and intima/medial layers is central to adverse vascular remodeling, plaque instability, and clinical events such as acute coronary syndromes.

Risk Factors

Risk factors for adventitial inflammation overlap with those for atherosclerosis, including traditional cardiovascular risk factors. Systemic autoimmune disorders (e.g., rheumatoid arthritis, lupus), chronic infections, and genetic predispositions may amplify adventitial immune activation. Environmental exposures, such as air pollution, and lifestyle factors, such as poor diet, can promote systemic and local vascular inflammation. Moreover, certain medications and therapeutic interventions, such as drug-eluting stents, may influence adventitial responses, highlighting the need for individualized risk stratification.

Clinical Features

Direct clinical manifestations of coronary adventitial inflammation are often subclinical, given the lack of nociceptive innervation in the vessel wall. However, its consequences are clinically significant, manifesting as progressive luminal narrowing, impaired vasomotor function, and increased risk of plaque rupture or erosion. Patients may present with stable angina, acute coronary syndromes, or silent ischemia. Inflammatory activity in the adventitia may also contribute to restenosis post-angioplasty and stent implantation, as well as late stent thrombosis.

Diagnosis

Definitive diagnosis of coronary adventitial inflammation remains challenging due to the limited accessibility of coronary tissue. Non-invasive imaging modalities, such as positron emission tomography (PET) with radiolabeled tracers (e.g., 18F-FDG, 68Ga-DOTATATE), can detect vascular inflammation but lack spatial resolution to localize activity to the adventitia. High-resolution intravascular ultrasound (IVUS), optical coherence tomography (OCT), and emerging molecular imaging techniques offer promise in visualizing adventitial changes and quantifying vasa vasorum proliferation. Blood biomarkers of systemic inflammation (e.g., hs-CRP, IL-6) serve as indirect indicators but lack specificity for coronary adventitial involvement.

Treatment & Management

Management strategies for adventitial inflammation align with those for coronary atherosclerosis, emphasizing risk factor modification, lipid-lowering therapy, antihypertensive agents, and antiplatelet medications. Statins, in addition to lipid-lowering, exhibit pleiotropic anti-inflammatory effects and may attenuate adventitial immune activation. Novel agents targeting inflammatory pathways (e.g., canakinumab, colchicine) have demonstrated efficacy in reducing cardiovascular events, likely by modulating both intimal and adventitial inflammation. Lifestyle interventions, including smoking cessation, dietary modification, and regular exercise, remain foundational.

Recent Advances / Emerging Therapies

Recent advances have focused on elucidating molecular pathways involved in adventitial inflammation. Inhibitors of the NLRP3 inflammasome, monoclonal antibodies targeting pro-inflammatory cytokines, and RNA-based therapeutics are under investigation. Imaging advances, such as hybrid PET/MRI and molecular contrast agents, offer improved sensitivity for detecting early adventitial changes. Local delivery of anti-inflammatory agents via drug-eluting balloons or stents is an area of active research, aiming to reduce restenosis and promote favorable remodeling. Studies on the modulation of the gut microbiome and its impact on vascular inflammation are also emerging, offering novel preventive strategies.

Guideline Recommendations

Major cardiovascular societies advocate aggressive management of traditional risk factors and the use of statins and antiplatelet therapy for patients at risk of CAD. While specific recommendations targeting adventitial inflammation are lacking, current guidelines emphasize the importance of inflammation as a therapeutic target. The 2021 ESC and 2019 ACC/AHA guidelines recognize the role of inflammation in atherosclerosis and endorse the use of anti-inflammatory therapies in selected high-risk patients. Ongoing trials may further inform future updates and personalized therapeutic algorithms.

Conclusion

Coronary adventitial inflammation is a pivotal driver of vascular remodeling, shaping the trajectory of atherosclerotic disease and clinical outcomes. Improved understanding of its mechanisms has opened new avenues for diagnosis and therapy, challenging clinicians to integrate evolving evidence into practice. Continued research and translational efforts are essential to refine risk stratification, develop targeted therapies, and ultimately improve cardiovascular health for patients worldwide.